Pilot study of a new matrix therapy agent (RGTA OTR4120®) in treatment-resistant corneal ulcers and corneal dystrophy;Étude pilote d'un nouvel agent de thérapie matricielle (RGTA OTR4120® ) dans les ulcères de cornée et les dystrophies cornéennes rebelles

Journal Francais d'Ophtalmologie

Volumn 31, Issue 5, 2008, Pages 465-471

  Khammari Chebbi, C ^a   Kichenin, K ^b   Amar, N ^a   Nourry, H ^a   Warnet, J M ^a   Barritault, D ^b   Baudouin, C ^a,c  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b OTR3 SAS   (France)

^c INSERM   (France)

Author keywords

Corneal dystrophy; Heparan mimetics; Keratitis; Matrix therapy; RGTA

Indexed keywords

EYE DROPS;

ARTICLE; CONGENITAL CORNEA DYSTROPHY; CORNEA ULCER; DRUG ADMINISTRATION; DRUG EFFECT; DRUG INSTILLATION; HUMAN; PILOT STUDY; WOUND HEALING;

CORNEAL DYSTROPHIES, HEREDITARY; CORNEAL ULCER; DRUG ADMINISTRATION SCHEDULE; HUMANS; INSTILLATION, DRUG; OPHTHALMIC SOLUTIONS; PILOT PROJECTS; WOUND HEALING;

EID: 45249101320     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(08)72462-8     Document Type: Article

References (40)

1. Baudouin C. A new approach for better comprehension of diseases of the ocular surface, J Fr Ophtalmol, 2007;30:239-46.
2. Baudouin C. The pathology of dry eye. Surv Ophthalmol, 2001;45(Suppl):11-20.
3. Ono SJ, Abelson MB. Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol, 2005;115:118-22.
4. Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology, 2004;111:1115-20.
5. Muraine M, Gueudry J, Toubeau D, Gardea E, Verspyck E, Menguy E, et al. [Advantages of amniotic membrane transplantation in eye surface diseases]. J Fr Ophtalmol, 2006;29:1070-83.
6. Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol, 2005;139:242-6.
7. Foulks GN. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin, 2006;46:105-22.
8. Klenkler B, Sheardown H, Jones L. Growth factors in the tear film: role in tissue maintenance, wound healing, and ocular pathology. Ocul Surf, 2007;5:228-39.
9. Lim M, Goldstein MH, Tuli S, Schultz GS. Growth factor, cytokine and protease interactions during corneal wound healing. Ocul Surf, 2003;1:53-65.
10. Imanishi J, Kamiyana K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res, 2000;19:113-9.
11. Yamada N, Yanai R, Kawamoto K, Nagano T, Nakamura M, Inui M, et al. Promotion of corneal epithelial wound healing by a tetrapeptide (SSSR) derived from IGF-1. Invest Ophthalmol Vis Sci, 2006;47:3286-92.
12. Micera A, Lambiase A, Puxeddu I, Aloe L, Stampachiacchiere B, Levi-Schaffer F, et al. Nerve growth factor effect on human primary fibroblastic-keratocytes: possible mechanism during corneal healing. Exp Eye Res, 2006;83:747-57.
13. Woo HM, Bentley E, Campbell SF, Marfurt CF, Murphy CJ. Nerve growth factor and corneal wound healing in dogs. Exp Eye Res, 2005;80:633-42.
14. Coassin M, Lambiase A, Costa N, De Gregorio A, Sgruletta R, Sacchetti M, et al. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. Graefes Arch Clin Exp Ophthalmol, 2005;243:151-5.
15. Yamada N, Yanai R, Inui M, Nishida T. Sensitizing effect of substance P on corneal epithelial migration induced by IGF-1, fibronectin, or interleukin-6. Invest Ophthalmol Vis Sci, 2005;46:833-9.
16. Cellini M, Bendo E, Bravetti GO, Campos EC. The use of nerve growth factor in surgical wound healing of the cornea. Ophthalmic Res, 2006;38:177-81.
17. Tan MH, Bryars J, Moore J. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration. Cornea, 2006;25:352-5.
18. Rouet V, Meddahi-Pellé A, Miao HQ, Vlodavsky I, Caruelle JP, Barritault D. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. J Biomed Mater Res, 2006, 15;78:792-7.
19. Barritault D, Caruelle J.-P. Les agents de régéné ration (ou RGTAs) : une nouvelle approche thérapeutique. Ann Pharm Fr, 2006;64:135-44.
20. Mestries P, Borchiellini C, Barbaud C, Duchesnay A, Escartin Q, Barritault D, et al. Chemically modified dextrans modulate expression of collagen phenotype by cultured smooth muscle cells in relation to the degree of carboximethyl, benzamide, and sulfatation substitutions. J Biomed Mater Res, 1998;42:286-94.
21. Mestries P, Alexakis C, Papy-Garcia D, Duchesnay A, Barritault D, Caruelle JP et al. Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factor-beta1. Matrix Biol, 2001;20:171-81.
22. Papy-Garcia D, Barbier-Chassefière V, Rouet V, Kerros ME, Klochendler C, Tournaire MC, et al. Non degradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparin sulfate mimetics. Macromolecules, 2005;38:4647-54.
23. Logeart-Avramoglou D, Huynh R, Chaubet F, Sedel L, Meunier A. Interaction of specifically chemically modified dextrans with transforming growth factor beta1: potentiation of its biological activity. Biochem Pharmacol, 2002;63:129-37.
24. Tardieu M, Gamby C, Avramoglou T, Jozfonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol, 1992;150:194-203.
25. Frank L, Lebreton-Decoster C, Godeau G, Coulomb B, Jozefonvicz J. Dextran derivatives modulate collagen matrix organization in dermal equivalent. J Biomater Sci Polym Ed. 2006;17:499-517.
26. Alexakis C, Mestries P, Garcia S, Petit E, Barbier V, Papy-Garcia D, et al. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta1. FASEB J. 2004;18:1147-9.
27. Ledoux D, Merciris D, Barritault D, Caruelle JP. Heparin-like dextran derivates as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G. FEBS, 2003;537:23-9.
28. Ledoux D, Papy-Garcia D, Escartin Q, Sagot MA, Cao Y, Barritault D, et al. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J Biol Chem, 2000;275:383-90.
29. Meddahi A, Lemdjabar H, Carue1le JP, Barritault D, Hornebeck W. FGF protection and inhibition of human neutrophil elastase by carboxylmethyl benzylamide sulfonate dextran derivates. Int J Biol Macromol, 1996;18:141-5.
30. Escartin Q, Lallam-Laroye C, Baroukh B, Morvan FO, Caruelle JP, Godeau G, et al. A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers. FASEB J, 2003;17:644-51.
31. Colombier ML, Lafont J, Blanquaert F, Caruelle JP, Barritault D, Saffar JL. A single low dose of RGTA, a new healing agent, hastens wound maturation and enhances bone deposition in rat craniotomy defects. Cells Tissues Organs, 1999;164:131-40.
32. Meddahi A, Brée F, Papy-Garcia D, Gautron J, Barritault D, Caruelle JP. Pharmacological studies of RGTA (11), a heparan sulfate mimetic polymer, efficient on muscle regeneration. J Biomed Mater Res, 2002;62:525-31.
33. Lafont J, Baroukh B, Berdal A, Colombier ML, Barritault D, Caruelle JP, et al. RGTA11, a new healing agent, triggers developmental events during healing of craniotomy defects in adult rats. Growth factors, 1998;16:23-38.
34. Meddahi A, Caruelle JP, Gold L, Rosso Y, Barritault D. New concepts in tissue repair: skin as an example. Diabetes Metab, 1996;22:274-8.
35. Meddahi A, Alexakis C, Papy D, Carue1le JP, Barritault D Barritault D. Heparin-like polymer improved healing of gastric and colic ulceration. J Biomed Mater Res, 2002;60:497-501.
36. Lallam-Laroy C, Escartin Q, Zlowodski AS, Barritault D, Caruelle JP, Baroukh B et al. Periodontitis destructions are restored by synthetic glycosaminoglycan mimetic. J Biomed Mater Res, 2006;79A:675-83.
37. Garcia-Felipe S, Barbier-Chassefière V, Alexakis C, Huet E, Ledoux D, Kerros ME et al. RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin. J Biomed Mater Res, 2007;80A:75-84.
38. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP, Heparan-like molecules induce the repair of skull defects. Bone, 1995;17:499-506.
39. Fredj-Reygrobellet D, Hristova DL, Ettaiche M, Meddahi A, Jozefowicz J, Barritault D. CMDBS, functional analogue of heparin sulphate as a new class of corneal ulcer healing agents. Ophthalmic Res, 1994;26:325-31.
40. Morvan FO, Baroukh B, Ledoux D, Caruelle JP, Barritault D, Godeau G, et al. An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters. Am J Pathol., 2004;164:739-46.